171 related articles for article (PubMed ID: 21205921)
41. Novel HER2 selective tyrosine kinase inhibitor, TAK-165, inhibits bladder, kidney and androgen-independent prostate cancer in vitro and in vivo.
Nagasawa J; Mizokami A; Koshida K; Yoshida S; Naito K; Namiki M
Int J Urol; 2006 May; 13(5):587-92. PubMed ID: 16771730
[TBL] [Abstract][Full Text] [Related]
42. Characterization of a transplantable hormone-responsive human prostatic cancer xenograft TEN12 and its androgen-resistant sublines.
Harper ME; Goddard L; Smith C; Nicholson RI
Prostate; 2004 Jan; 58(1):13-22. PubMed ID: 14673948
[TBL] [Abstract][Full Text] [Related]
43. Interruption of nuclear factor kappaB signaling by the androgen receptor facilitates 12-O-tetradecanoylphorbolacetate-induced apoptosis in androgen-sensitive prostate cancer LNCaP cells.
Altuwaijri S; Lin HK; Chuang KH; Lin WJ; Yeh S; Hanchett LA; Rahman MM; Kang HY; Tsai MY; Zhang Y; Yang L; Chang C
Cancer Res; 2003 Nov; 63(21):7106-12. PubMed ID: 14612503
[TBL] [Abstract][Full Text] [Related]
44. Rho/ROCK/actin signaling regulates membrane androgen receptor induced apoptosis in prostate cancer cells.
Papadopoulou N; Charalampopoulos I; Alevizopoulos K; Gravanis A; Stournaras C
Exp Cell Res; 2008 Oct; 314(17):3162-74. PubMed ID: 18694745
[TBL] [Abstract][Full Text] [Related]
45. Relaxin receptor antagonist AT-001 synergizes with docetaxel in androgen-independent prostate xenografts.
Neschadim A; Pritzker LB; Pritzker KP; Branch DR; Summerlee AJ; Trachtenberg J; Silvertown JD
Endocr Relat Cancer; 2014 Jun; 21(3):459-71. PubMed ID: 24812057
[TBL] [Abstract][Full Text] [Related]
46. Targeting prostate cancer with HTI-286, a synthetic analog of the marine sponge product hemiasterlin.
Hadaschik BA; Ettinger S; Sowery RD; Zoubeidi A; Andersen RJ; Roberge M; Gleave ME
Int J Cancer; 2008 May; 122(10):2368-76. PubMed ID: 18240145
[TBL] [Abstract][Full Text] [Related]
47. Androgen causes growth suppression and reversion of androgen-independent prostate cancer xenografts to an androgen-stimulated phenotype in athymic mice.
Chuu CP; Hiipakka RA; Fukuchi J; Kokontis JM; Liao S
Cancer Res; 2005 Mar; 65(6):2082-4. PubMed ID: 15781616
[TBL] [Abstract][Full Text] [Related]
48. Inhibition of tumor growth and progression of LNCaP prostate cancer cells in athymic mice by androgen and liver X receptor agonist.
Chuu CP; Hiipakka RA; Kokontis JM; Fukuchi J; Chen RY; Liao S
Cancer Res; 2006 Jul; 66(13):6482-6. PubMed ID: 16818617
[TBL] [Abstract][Full Text] [Related]
49. Zyflamend, a combination of herbal extracts, attenuates tumor growth in murine xenograft models of prostate cancer.
Huang EC; McEntee MF; Whelan J
Nutr Cancer; 2012; 64(5):749-60. PubMed ID: 22663543
[TBL] [Abstract][Full Text] [Related]
50. Androgen receptor and E2F-1 targeted thymoquinone therapy for hormone-refractory prostate cancer.
Kaseb AO; Chinnakannu K; Chen D; Sivanandam A; Tejwani S; Menon M; Dou QP; Reddy GP
Cancer Res; 2007 Aug; 67(16):7782-8. PubMed ID: 17699783
[TBL] [Abstract][Full Text] [Related]
51. Aberrant activation of androgen receptor in a new neuropeptide-autocrine model of androgen-insensitive prostate cancer.
Yang JC; Ok JH; Busby JE; Borowsky AD; Kung HJ; Evans CP
Cancer Res; 2009 Jan; 69(1):151-60. PubMed ID: 19117998
[TBL] [Abstract][Full Text] [Related]
52. Inhibition of orthotopic growth and metastasis of androgen-sensitive human prostate tumors in mice by bioactive soybean components.
Zhou JR; Yu L; Zhong Y; Nassr RL; Franke AA; Gaston SM; Blackburn GL
Prostate; 2002 Oct; 53(2):143-53. PubMed ID: 12242729
[TBL] [Abstract][Full Text] [Related]
53. Phenoxodiol inhibits growth of metastatic prostate cancer cells.
Aguero MF; Venero M; Brown DM; Smulson ME; Espinoza LA
Prostate; 2010 Aug; 70(11):1211-21. PubMed ID: 20564423
[TBL] [Abstract][Full Text] [Related]
54. Activation of membrane androgen receptors potentiates the antiproliferative effects of paclitaxel on human prostate cancer cells.
Kampa M; Kogia C; Theodoropoulos PA; Anezinis P; Charalampopoulos I; Papakonstanti EA; Stathopoulos EN; Hatzoglou A; Stournaras C; Gravanis A; Castanas E
Mol Cancer Ther; 2006 May; 5(5):1342-51. PubMed ID: 16731768
[TBL] [Abstract][Full Text] [Related]
55. The radiation response of hormone-resistant prostate cancer induced by long-term hormone therapy.
Wu CT; Chen WC; Liao SK; Hsu CL; Lee KD; Chen MF
Endocr Relat Cancer; 2007 Sep; 14(3):633-43. PubMed ID: 17914094
[TBL] [Abstract][Full Text] [Related]
56. The human prostate cancer cell line LNCaP bears functional membrane testosterone receptors that increase PSA secretion and modify actin cytoskeleton.
Kampa M; Papakonstanti EA; Hatzoglou A; Stathopoulos EN; Stournaras C; Castanas E
FASEB J; 2002 Sep; 16(11):1429-31. PubMed ID: 12205037
[TBL] [Abstract][Full Text] [Related]
57. Differential effects of blueberry proanthocyanidins on androgen sensitive and insensitive human prostate cancer cell lines.
Schmidt BM; Erdman JW; Lila MA
Cancer Lett; 2006 Jan; 231(2):240-6. PubMed ID: 16399225
[TBL] [Abstract][Full Text] [Related]
58. Combination of Quercetin and 2-Methoxyestradiol Enhances Inhibition of Human Prostate Cancer LNCaP and PC-3 Cells Xenograft Tumor Growth.
Yang F; Song L; Wang H; Wang J; Xu Z; Xing N
PLoS One; 2015; 10(5):e0128277. PubMed ID: 26011145
[TBL] [Abstract][Full Text] [Related]
59. White button mushroom (Agaricus bisporus) exhibits antiproliferative and proapoptotic properties and inhibits prostate tumor growth in athymic mice.
Adams LS; Phung S; Wu X; Ki L; Chen S
Nutr Cancer; 2008; 60(6):744-56. PubMed ID: 19005974
[TBL] [Abstract][Full Text] [Related]
60. Second-generation testosterone-platinum(II) hybrids for site-specific treatment of androgen receptor positive prostate cancer: Design, synthesis and antiproliferative activity.
Ouellette V; Côté MF; Gaudreault RC; Tajmir-Riahi HA; Bérubé G
Eur J Med Chem; 2019 Oct; 179():660-666. PubMed ID: 31279298
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
